These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26432484)

  • 1. Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
    Oh PC; Ahn T; Kim DW; Hong BK; Kim DS; Kwan J; Choi CU; Yang YM; Bae JH; Jung KT; Choi WG; Jeon DW; Cho DK; Pyun WB; Cha KS; Cha TJ; Chun KJ; Kim YD; Kim BS; Kim DI; Kim TI
    Int J Cardiol; 2016 Jan; 202():331-5. PubMed ID: 26432484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
    Lim S; Kim PJ; Baek C; Kim TH; Koh YS; Park HJ; Kim HY; Chang K; Chung WS; Seung KB
    Clin Drug Investig; 2015 Dec; 35(12):833-42. PubMed ID: 26507618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
    Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
    Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
    Koh JS; Park Y; Tantry US; Ahn JH; Kang MG; Kim K; Jang JY; Park HW; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA; Jeong YH
    Platelets; 2017 Mar; 28(2):187-193. PubMed ID: 27560946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.
    Lim WH; Chae IH; Yoon CH; Choi DJ; Lim SW; Park WJ; Doh JH; Kim SH; Kim MA; Lee SH; Yoon JH; Ahn YK; Hyon MS; Kim KS; Kim YK; Lee HC; Seol SH; Hwang KK; Choi SW; Han KR; Shin ES; Kim SW; Lee BK; Kim HS
    Thromb Haemost; 2016 Jul; 116(1):78-86. PubMed ID: 27029284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
    Lee S; Lee HY; Park KW; Kang HJ; Koo BK; Kim HS; Choi DJ; Kim MA; Oh BH
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):413-24. PubMed ID: 23913405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
    Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY
    Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation.
    Cho YK; Nam CW; Park HS; Yoon HJ; Kim H; Hur SH; Kim YN; Lee JH; Yang DH; Lee BR; Jung BC; Kim W; Park JS; Lee JB; Kim KS; Kim KB
    Korean J Intern Med; 2014 Mar; 29(2):210-6. PubMed ID: 24648804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
    Giustino G; Redfors B; Kirtane AJ; Mehran R; Dangas GD; Witzenbichler B; Neumann FJ; Weisz G; Généreux P; Maehara A; McAndrew T; Farhan S; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Gurbel P; Ben-Yehuda O; Stone GW
    JACC Cardiovasc Interv; 2018 Jul; 11(13):1277-1286. PubMed ID: 29908967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
    Jin HY; Yang TH; Kim DI; Chung SR; Seo JS; Jang JS; Kim DK; Kim DK; Kim KH; Seol SH; Nam CW; Hur SH; Kim W; Park JS; Kim YJ; Kim DS
    Int J Cardiol; 2013 Sep; 167(5):1877-81. PubMed ID: 22682702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
    Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.